Latest Sanofi Stories

OTTAWA, Sept. 14, 2012 /CNW/ - As a follow-up to our July 11, 2012 communication on the cancer bladder treatment ImmuCyst, Health Canada has cleared for release one lot of the product that was being held due to problems in the facility where it was produced. The lot contains 1,500 doses for Canadian patients across Canada. Health Canada has authorized the release of lot #C4040AA after Departmental experts' thorough review determined that there is no direct evidence of microbial...

SWIFTWATER, Pa., Sept. 12, 2012 /PRNewswire/ -- Sanofi Pasteur and Actor Chris O'Donnell are teaming up to raise awareness about the seriousness of influenza and available vaccine options for adults 18 through 64 years of age, including Fluzone(® )Intradermal vaccine. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/57037-sanofi-pasteur-chris-o-donnell-fluzone-intradermal-influenza-virus-vaccine (Photo:...

LONDON, September 6, 2012 /PRNewswire/ -- Leading biotech and biopharma organisations are coming together to learn how to maximise their viral security strategies and the new technologies available from the FDA, NIBSC, NIH and a range of industry experts including Genzyme, Baxter and Amgen at the Pathogen Safety Summit this November. Pharma IQ's Pathogen Safety Summit is back for its third year to offer the opportunity to learn and hear insights from key regulatory...

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Aug. 29, 2012 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma® Gene Expression Classifier to be offered to patients in the state. The companies also announced that Memorial Sloan-Kettering Cancer...

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's...

$500,000 Will Promote Benefits of Self-Management WASHINGTON, Aug. 28, 2012 /PRNewswire-USNewswire/ -- Sanofi has awarded a $500,000 grant to the National Council on Aging (NCOA) to support its efforts to improve the health and independence of millions of older adults with multiple chronic conditions. (Logo: http://photos.prnewswire.com/prnh/20100615/NCOALOGO) Chronic diseases account for 75% of our nation's health care costs, with nearly half of all older adults living...

PARSIPPANY, N.J. and MUMBAI, India, Aug. 14, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of Benign Prostatic Hyperplasia or enlarged prostate. Alfuzosin is the generic name for the brand Uroxatral(®), marketed in the United States by Sanofi-Aventis. Wockhardt is launching...

PARIS, Aug. 13, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection...

OXFORD, England, August 8, 2012 /PRNewswire/ -- -- Treatment of final RetinoStat(R)patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, and its partner Sanofi (EURONEXT: SAN and NYSE: SNY) today announce a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen(TM) Phase I/IIa study in Stargardt...

OXFORD, England, July 23, 2012 /PRNewswire/ -- -- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical...